- Home
- IPA vs CGTX Comparison
IPA vs CGTX Comparison
Compare IPA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- CGTX
- Stock Information
- Founded
- IPA 1983
- CGTX 2007
- Country
- IPA United States
- CGTX United States
- Employees
- IPA N/A
- CGTX N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- CGTX Health Care
- Exchange
- IPA Nasdaq
- CGTX Nasdaq
- Market Cap
- IPA 20.6M
- CGTX 23.1M
- IPO Year
- IPA 2017
- CGTX 2021
- Fundamental
- Price
- IPA $0.45
- CGTX $0.30
- Analyst Decision
- IPA Strong Buy
- CGTX Strong Buy
- Analyst Count
- IPA 2
- CGTX 5
- Target Price
- IPA $4.00
- CGTX $6.13
- AVG Volume (30 Days)
- IPA 407.1K
- CGTX 803.7K
- Earning Date
- IPA 03-28-2025
- CGTX 05-07-2025
- Dividend Yield
- IPA N/A
- CGTX N/A
- EPS Growth
- IPA N/A
- CGTX N/A
- EPS
- IPA N/A
- CGTX N/A
- Revenue
- IPA $16,581,105.00
- CGTX N/A
- Revenue This Year
- IPA $4.67
- CGTX N/A
- Revenue Next Year
- IPA $14.15
- CGTX N/A
- P/E Ratio
- IPA N/A
- CGTX N/A
- Revenue Growth
- IPA 1.34
- CGTX N/A
- 52 Week Low
- IPA $0.27
- CGTX $0.31
- 52 Week High
- IPA $1.36
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- IPA 52.32
- CGTX 31.49
- Support Level
- IPA $0.45
- CGTX $0.40
- Resistance Level
- IPA $0.48
- CGTX $0.47
- Average True Range (ATR)
- IPA 0.03
- CGTX 0.04
- MACD
- IPA 0.00
- CGTX -0.01
- Stochastic Oscillator
- IPA 55.57
- CGTX 11.16
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.